As filed with the Securities and Exchange Commission on July 14, 2017.

 

Registration No. 333-214863

 

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

MEDICAL TRANSCRIPTION BILLING, CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   7389   22-3832302

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

 

 

 

7 Clyde Road

Somerset, New Jersey 08873

(732) 873-5133

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

 

Mahmud Haq
Chief Executive Officer

7 Clyde Road

Somerset, New Jersey 08873

(732) 873-5133

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies of communications to:

 

David S. Song, Esq.

Mazzeo Song P.C.

444 Madison Avenue, 4th Floor

New York, New York 10022

(212) 599-0700

 

 

 

Approximate date of commencement of proposed sale to the public: This post-effective amendment is being filed to deregister all of the unsold securities previously registered under the Registration Statement.

 

 

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. [  ]

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [  ]

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [  ]

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ]   Accelerated filer [  ]
Non-Accelerated filer [  ] (Do not check if a smaller reporting company) Smaller reporting company [X]
Emerging growth company [X]

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.[X]

 

 

 

 
 

 

EXPLANATORY NOTE

 

On December 1, 2016, Medical Transcription Billing, Corp. (the “Company”) filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC), File No. 333-214863, as amended by Amendment No. 1 to Form S-1 filed on December 12, 2016, Amendment No. 2 to Form S-1 filed on June 2, 2017, Amendment No. 3 to Form S-1 filed on June 14, 2017, and Amendment No. 4 to Form S-1 filed on June 20, 2017 (the “Registration Statement”), to register the sale of the Company’s Series A Preferred Stock. The Registration Statement was declared effective on June 22, 2017.

 

The Company is filing this Post-Effective Amendment No. 1 to the Registration Statement to deregister all of the shares of Series A Preferred Stock that have not been sold pursuant to the Registration Statement. Pursuant to the undertaking contained in the Registration Statement to remove from registration any of the securities being registered which remain unsold at the termination of the offering, the Company hereby amends the Registration Statement to remove from registration the shares of Series A Preferred Stock covered by the Registration Statement which remain unsold.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Name   Title   Date
         
/s/ Mahmud Haq   Chairman of the Board and Chief Executive   July 14, 2017
Mahmud Haq   Officer (principal executive officer)    
         
/s/ Bill Korn   Chief Financial Officer   July 14, 2017
Bill Korn   (principal financial officer)    
         
/s/ Norman Roth   Controller (principal accounting officer)   July 14, 2017
Norman Roth        
         
/s/ Stephen A. Snyder   President and Director   July 14, 2017
Stephen A. Snyder        
         
*   Director   July 14, 2017
Anne Busquet        
         
*   Director   July 14, 2017
Howard L. Clark, Jr.        
         
*   Director   July 14, 2017
John N. Daly        
         
*   Director   July 14, 2017
Cameron Munter        

 

* By: /s/ Mahmud Haq     July 14, 2017
  Mahmud Haq      
 

Attorney-in-Fact